- Standardized definitions established: Four consensus disease states—LDA, vLDA, on-drug complete control, and off-drug remission—were defined using validated clinical and patient-reported measures.
- Multidimensional framework: Disease activity incorporates both clinician-assessed signs (vIGA-AD/EASI) and patient-reported itch (PP-NRS), reflecting AD’s clinical and symptomatic burden.
- Time-based criteria matter: On-drug complete control requires ≥6 months of sustained control, while off-drug remission requires ≥12 months after stopping therapy.
- Supports trial and regulatory alignment: These definitions enable more consistent endpoints, improving comparability across clinical trials and facilitating regulatory evaluation.
- Advances treat-to-target care: The framework provides clinically meaningful benchmarks to guide long-term disease management and therapeutic decision-making in AD.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
